MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Last update at 2024-07-25T16:53:00Z
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
Tue 23 Jul 24, 08:05 PM7 Cheap Biotech Stocks With Major Upside Potential
Tue 09 Jul 24, 12:00 AMThe Top 3 Biotech Stocks to Buy in April 2024
Sat 27 Apr 24, 11:00 AMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 234.35M | 294.15M | 130.84M | 398.11M | 452.09M |
Minority interest | - | - | - | - | - |
Net income | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M |
Selling general administrative | 459.86M | 401.71M | 293.36M | 228.24M | 206.37M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 1553.15M | 1382.10M | 951.27M | 934.68M | 827.48M |
Reconciled depreciation | 20.88M | 13.63M | 9.14M | 8.35M | 7.77M |
Ebit | 180.61M | 273.04M | 100.92M | 361.12M | 444.32M |
Ebitda | 201.48M | 286.67M | 110.06M | 369.47M | 452.09M |
Depreciation and amortization | 20.88M | 13.63M | 9.14M | 8.35M | 7.77M |
Non operating income net other | -0.19700M | -0.18400M | 0.91M | 0.68M | 0.40M |
Operating income | 201.48M | 286.67M | 110.06M | 369.47M | 438.86M |
Other operating expenses | 1409.58M | 1148.30M | 877.48M | 598.30M | 414.97M |
Interest expense | 53.74M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
Tax provision | 52.07M | 63.09M | 19.06M | 77.10M | -237.97800M |
Interest income | 33.06M | 7.67M | 19.86M | 27.96M | 12.84M |
Net interest income | 33.06M | 7.67M | 19.86M | 27.96M | 12.84M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 52.07M | 63.09M | 19.06M | 77.10M | -237.97800M |
Total revenue | 1611.06M | 1434.97M | 987.54M | 967.77M | 853.83M |
Total operating expenses | 1351.67M | 1095.43M | 841.21M | 565.21M | 388.62M |
Cost of revenue | 57.91M | 52.87M | 36.27M | 33.10M | 26.35M |
Total other income expense net | 32.87M | 7.49M | 20.78M | 28.64M | 13.24M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M |
Net income applicable to common shares | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 2942.36M | 3071.49M | 2616.24M | 2137.33M | 1885.67M |
Intangible assets | - | - | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 67.93M | 62.21M | 57.53M | 57.01M | 26.99M |
Total liab | 678.45M | 583.06M | 405.62M | 258.22M | 199.70M |
Total stockholder equity | 2263.91M | 2488.43M | 2210.61M | 1879.11M | 1685.97M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 329.39M | 285.11M | 313.33M | 181.03M | 21.72M |
Common stock | 0.30M | 0.32M | 0.32M | 0.31M | 0.30M |
Capital stock | 0.30M | 0.32M | 0.32M | 0.31M | 0.30M |
Retained earnings | -173.35100M | -34.22500M | -216.50700M | -447.57000M | -559.35100M |
Other liab | - | 68.53M | 16.76M | 4.48M | 8.94M |
Good will | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M |
Other assets | - | 286.88M | 197.54M | 187.11M | 185.32M |
Cash | 262.99M | 501.19M | 647.17M | 319.22M | 266.50M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 394.28M | 324.36M | 337.59M | 204.66M | 142.75M |
Current deferred revenue | 5.41M | 6.58M | 8.74M | - | 106.72M |
Net debt | -73.05000M | -311.02500M | -595.89700M | -270.13100M | -215.76200M |
Short term debt | 25.71M | - | -8.73900M | - | 2.73M |
Short long term debt | - | - | - | - | - |
Short long term debt total | 189.94M | 190.17M | 51.27M | 49.09M | 50.74M |
Other stockholder equity | 2440.71M | 2536.85M | 2427.56M | 2321.89M | 2241.95M |
Property plant equipment | - | 110.62M | 149.15M | 67.38M | 48.89M |
Total current assets | 1317.96M | 1618.76M | 1834.75M | 1445.39M | 1011.19M |
Long term investments | 728.72M | 756.73M | 371.11M | 332.31M | 536.38M |
Net tangible assets | - | 2424.74M | 2048.76M | 1815.43M | 1622.29M |
Short term investments | 732.31M | 807.27M | 819.90M | 887.32M | 585.74M |
Net receivables | 237.41M | 214.78M | 282.65M | 160.88M | 119.07M |
Long term debt | - | - | - | - | - |
Inventory | 17.32M | 33.30M | 27.49M | 20.97M | 12.89M |
Accounts payable | 33.77M | 32.67M | 24.26M | 23.63M | 11.58M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -3.75000M | -14.52100M | -0.75800M | 4.48M | 3.07M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | 0.32M | - | 0.31M | 0.30M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | -34.22500M | - | -447.57000M | -559.35100M |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | - | 290.58M | 131.00M | 71.85M | 11.31M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 1624.40M | 1452.73M | 781.49M | 691.94M | 874.48M |
Capital lease obligations | 189.94M | 190.17M | 51.27M | 49.09M | 50.74M |
Long term debt total | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Investments | -334.47400M | -385.95800M | 21.34M | -100.87000M | -574.41300M |
Change to liabilities | - | -37.22300M | 66.10M | 51.11M | 44.12M |
Total cashflows from investing activities | - | -524.41400M | -42.88400M | -131.21500M | -587.24700M |
Net borrowings | - | - | - | - | - |
Total cash from financing activities | -546.05200M | 0.59M | -14.80100M | -25.13200M | 12.55M |
Change to operating activities | - | -91.32400M | 30.42M | -25.83100M | -5.72300M |
Net income | 207.76M | 182.28M | 231.06M | 111.78M | 321.01M |
Change in cash | -239.68300M | -161.21400M | 343.12M | 52.63M | -47.73800M |
Begin period cash flow | 502.68M | 663.89M | 320.77M | 268.14M | 315.88M |
End period cash flow | 262.99M | 502.68M | 663.89M | 320.77M | 268.14M |
Total cash from operating activities | 333.32M | 362.61M | 400.80M | 208.98M | 526.96M |
Issuance of capital stock | - | - | - | - | - |
Depreciation | 25.72M | 20.88M | 13.63M | 9.14M | 8.35M |
Other cashflows from investing activities | - | -110.75000M | -10.00000M | -10.00000M | -574.41300M |
Dividends paid | - | - | - | - | - |
Change to inventory | -12.97700M | -11.68300M | -13.20900M | -21.89700M | -5.73100M |
Change to account receivables | -22.62300M | 66.85M | -122.32400M | -42.47000M | 43.72M |
Sale purchase of stock | -579.50000M | 23.89M | -39.10800M | -50.01800M | 22.50M |
Other cashflows from financing activities | 33.45M | -47.18600M | 24.31M | 24.89M | -32.44500M |
Change to netincome | - | 153.94M | 195.12M | 123.37M | 127.69M |
Capital expenditures | 162.97M | 138.46M | 64.22M | 30.34M | 12.83M |
Change receivables | - | 66.85M | - | -42.47000M | 43.72M |
Cash flows other operating | - | -12.42700M | - | -22.05200M | -12.20500M |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | -161.21400M | - | 52.63M | -47.73800M |
Change in working capital | -13.97300M | -12.79900M | -39.01300M | -40.14000M | 67.08M |
Stock based compensation | 106.34M | 107.57M | 119.82M | 105.07M | 56.60M |
Other non cash items | 140.68M | 125.04M | 28.77M | 7.87M | 2.91M |
Free cash flow | 170.35M | 224.16M | 336.58M | 178.64M | 514.12M |
Sector: Healthcare Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
EXEL Exelixis Inc |
0.58 2.60% | 22.93 | 31.29 | 17.67 | 3.78 | 3.06 | 3.34 | 31.08 |
NVO Novo Nordisk A/S |
-2.29 1.74% | 129.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
NONOF Novo Nordisk A/S |
3.80 2.90% | 135.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
VRTX Vertex Pharmaceuticals Inc |
3.67 0.75% | 494.48 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
REGN Regeneron Pharmaceuticals Inc |
22.92 2.16% | 1083.78 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
1851 Harbor Bay Parkway, Alameda, CA, United States, 94502
Name | Title | Year Born |
---|---|---|
Dr. Stelios Papadopoulos Ph.D. | Co-Founder & Independent Chair of the Board | 1948 |
Dr. Michael M. Morrissey Ph.D. | CEO, Pres & Director | 1961 |
Mr. Christopher J. Senner | Exec. VP & CFO | 1968 |
Dr. Peter Lamb Ph.D. | Exec. VP of Scientific Strategy & Chief Scientific Officer | 1961 |
Mr. Jeffrey J. Hessekiel J.D. | Exec. VP, Gen. Counsel & Sec. | 1969 |
Mr. Patrick J. Haley M.B.A., MBA | Exec. VP of Commercial | 1976 |
Dr. Dana T. Aftab Ph.D. | Exec. VP of Bus. Operations | NA |
Ms. Susan T. Hubbard | Exec. VP of Public Affairs & Investor Relations | NA |
Mr. Gregg Bernier | VP of Marketing | NA |
Ms. Laura Dillard | Exec. VP of HR | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.